NCT05375903 2026-01-14A Phase 1 Dose-escalation Study of UGN-301 in Patients With Recurrent Non-muscle Invasive Bladder Cancer (NMIBC)UroGen Pharma Ltd.Phase 1 Completed51 enrolled